Research and Markets has announced the addition of the "Endometriosis - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 38 companies including many key and niche players such as

  • AbbVie Inc. (US)
  • AEterna Zentaris Inc. (Canada)
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • Bayer HealthCare Pharmaceuticals, Inc. (US)
  • Debiopharm Group (Switzerland)
  • Evotec AG (Germany)
  • Kissei Pharmaceutical Co., Ltd. (Japan)
  • Neurocrine Biosciences, Inc. (US)
  • ObsEva SA (Switzerland)
  • Pfizer, Inc. (US)
  • Repros Therapeutics, Inc. (US)
  • Roivant Sciences Ltd. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • ValiRx Plc (UK)

Key Topics Covered:

1. Industry Overview

2. Endometriosis & Its Treatment - An Overview

3. Treatment Of Endometriosis

4. Select Clinical Trials/Product Innovations & Approvals

5. Recent Industry Activity

6. Focus On Select Global Players

7. Global Market Perspective

Total Companies Profiled: 38 (including Divisions/Subsidiaries 40)

  • The United States (11)
  • Canada (3)
  • Japan (6)
  • Europe (15)
  • - France (1)
  • - Germany (3)
  • - The United Kingdom (2)
  • - Rest of Europe (9)
  • Asia-Pacific (Excluding Japan) (4)
  • Middle-East (1)

For more information about this report visit http://www.researchandmarkets.com/research/cv9r89/endometriosis